Annals of Nuclear Medicine最新文献

{"title":"Evaluation of 68Ga-PSMA-11 PET/CT: a Phase 1 clinical study in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer","authors":"Anri Inaki,&nbsp;Atsushi Mizokami,&nbsp;Hiroshi Wakabayashi,&nbsp;Kouji Izumi,&nbsp;Yoshifumi Kadono,&nbsp;Tadashi Toyama,&nbsp;Shizuko Takahara,&nbsp;Toshinori Murayama,&nbsp;Seigo Kinuya","doi":"10.1007/s12149-024-01931-7","DOIUrl":"10.1007/s12149-024-01931-7","url":null,"abstract":"<div><h3>Background</h3><p>Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals allow whole-body imaging to detect prostate cancer (PC). Positron emission tomography imaging using gallium-68 (⁶⁸Ga)-PSMA-11 has been shown to have a favorable safety and tolerability profile and high diagnostic performance. The study evaluates the safety and pharmacokinetics of ⁶⁸Ga-PSMA-11 in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer.</p><h3>Methods</h3><p>This single arm study enrolled Japanese patients with primary PC (<i>n</i> = 3), suspected recurrent PC following radical prostatectomy (<i>n</i> = 4), or suspected recurrent PC following radical radiotherapy (<i>n</i> = 3). All patients received a single intravenous dose of ⁶⁸Ga-PSMA-11 2.0 MBq/kg (±10%) followed by PSMA PET imaging and safety and pharmacokinetic evaluations. Based on the blood concentrations of ⁶⁸Ga-PSMA-11 and the radioactivity distribution rate in each organ/tissue, the absorbed doses in major organs/tissues and the whole-body effective dose were calculated by the Medical Internal Radiation Dose method.</p><h3>Results</h3><p>Ten patients were enrolled. Mean age was 73.3 ± 4.8 years, and median prostate-specific antigen was 8.250 ng/mL. Five patients (50%) experienced a total of 6 adverse events, and no grade ≥ 2 adverse events or serious adverse events were reported. No clinically significant changes in vital signs, haematology parameters, or blood chemistry or ECG abnormalities were observed. The estimated whole body effective dose of ⁶⁸Ga-PSMA-11 (mean ± standard deviation) was 2.524 × 10^–2 ± 2.546 × 10^–3 mSv/MBq. Time to maximum concentration (1.16 × 10^–4 ± 1.3 × 10^–5% ID/mL) in whole blood was 2.15 ± 0.33 min.</p><h3>Conclusions</h3><p>⁶⁸Ga-PSMA-11 has a favourable safety and tolerability profile in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer, which is comparable to previous observations in other populations.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 8","pages":"587 - 595"},"PeriodicalIF":2.5,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11281955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140943882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of F-18 FDG PET/CT in differentiating autoimmune pancreatitis from pancreatic cancer: a systemic review and meta-analysis","authors":"Deepanksha Datta,&nbsp;B. Selvakumar,&nbsp;Akhil Dhanesh Goel,&nbsp;Sanskriti Chhibber,&nbsp;Vaibhav Kumar Varshney,&nbsp;Rajesh Kumar","doi":"10.1007/s12149-024-01934-4","DOIUrl":"10.1007/s12149-024-01934-4","url":null,"abstract":"<div><h3>Objectives</h3><p>This study aims to evaluate the utility of F-18 FDG PET/CT in the non-invasive diagnosis of autoimmune pancreatitis (AIP) and differentiating it from pancreatic cancer (CaP) based on the amount and pattern of FDG uptake, as well as involvement of extra-pancreatic sites.</p><h3>Methods</h3><p>A systematic search was conducted using PubMed, Scopus, Cochrane Library and Google Scholar. Only those studies that compared the findings of F-18 FDG PET/CT in terms of SUVmax, pattern of FDG uptake and presence of FDG-avid extra-pancreatic sites in both AIP and CaP were included. Studies were qualitatively assessed for risk of bias and publication bias. The diagnostic performance of parameters on PET/CT was examined through pooled sensitivity, specificity, diagnostic odd’s ratio (DOR) and summary receiver operator characteristic (SROC) curve analysis.</p><h3>Results</h3><p>Six studies were included with a total of 580 patients. 178 patients had AIP (Age 18–90 years, male, M: female, F ratio—8.4:1) and 402 patients had CaP (Age 22–88 years, M:F ratio-1.5:1). Type of AIP was reported in only 3 studies, with the included cases predominantly being type 1 AIP. All studies were retrospective with heterogeneity and a risk on patient selection and index test. The FDG uptake, expressed as SUVmax, was lower in AIP with a weighted mean difference of −3.11 (95% confidence interval, CI: −5.28 to −0.94). To diagnose AIP, the pooled sensitivity, specificity and DOR of diffuse pattern of FDG uptake were 0.59 (95% CI: 0.51–0.66), 0.89 (95% CI: 0.86–0.92) and 21.07 (95% CI: 5.07–88.32), respectively, with an area under curve (AUC) of 0.717 on SROC analysis. The pooled sensitivity, specificity and DOR of FDG-avid extra pancreatic sites were 0.55 (95% CI: 0.45–0.65), 0.58 (95% CI: 0.52–0.64) and 2.33 (95% CI: 1.40–3.89), respectively, with an AUC of 0.632.</p><h3>Conclusion</h3><p>On F-18 FDG PET/CT, a pancreatic lesion of AIP has a lower SUVmax value than CaP. A diffuse pattern of FDG uptake and presence of an extra-pancreatic FDG-avid site are nearly 21 times and twice more likely in AIP than CaP, respectively.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 8","pages":"619 - 629"},"PeriodicalIF":2.5,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140943880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of lymph node to primary tumor standardized uptake value ratio in cancer patients: a meta-analysis","authors":"Wing-Keen Yap,&nbsp;Ken-Hao Hsu,&nbsp;Ting-Hao Wang,&nbsp;Chia-Hsin Lin,&nbsp;Chung-Jan Kang,&nbsp;Shih-Ming Huang,&nbsp;Huan-Chun Lin,&nbsp;Tsung-Min Hung,&nbsp;Kai-Ping Chang,&nbsp;Tsung-You Tsai","doi":"10.1007/s12149-024-01933-5","DOIUrl":"10.1007/s12149-024-01933-5","url":null,"abstract":"<div><h3>Objective</h3><p>The lymph node to primary tumor standardized uptake value ratio (NTR) is an innovative parameter derived from positron emission tomography/computed tomography (PET/CT) scans that captures the intricate relationship between primary tumors and associated lymph nodes. This meta-analysis aimed to investigate the prognostic value of NTR in cancer patients.</p><h3>Methods</h3><p>A systematic search of PubMed, Cochrane, and Embase databases was conducted to identify studies investigating the association between NTR and survival outcomes in cancer patients. The pooled adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) were calculated using a random-effects model.</p><h3>Results</h3><p>Twelve studies comprising a total of 2037 patients were included in the meta-analysis. Elevated NTR was significantly associated with worse overall survival aHR (2.21, 95% CI 1.63 to 2.99), disease-free survival aHR (3.27, 95% CI 2.12 to 5.05), and distant metastasis-free survival aHR (2.07, 95% CI 1.55 to 2.78) in cancer patients. Subgroup analyses by cancer type showed consistent results across various malignancies, including head and neck squamous cell carcinoma, endometrial carcinoma, lung cancer, breast cancer, and nasopharyngeal carcinoma.</p><h3>Conclusions</h3><p>This meta-analysis provides evidence for a significant association between elevated NTR and worse survival outcomes in cancer patients. Elevated NTR may serve as a useful prognostic biomarker for cancer patients and could potentially be used to guide treatment decisions and monitor disease progression. Future studies should aim to validate these findings in larger and more diverse patient populations and investigate the underlying mechanisms for the observed association between NTR and survival outcomes.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 8","pages":"607 - 618"},"PeriodicalIF":2.5,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140896890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"11C-Methionine uptake in meningiomas after stereotactic radiotherapy","authors":"Hanne-Rinck Jeltema,&nbsp;Bart R. J. van Dijken,&nbsp;Katalin Tamási,&nbsp;Gea Drost,&nbsp;Mart A. A. M. Heesters,&nbsp;Anouk van der Hoorn,&nbsp;Andor W. J. M. Glaudemans,&nbsp;J. Marc C. van Dijk","doi":"10.1007/s12149-024-01932-6","DOIUrl":"10.1007/s12149-024-01932-6","url":null,"abstract":"<div><h3>Objective</h3><p>¹¹C-Methionine positron emission tomography (MET-PET) is used for stereotactic radiotherapy planning in meningioma patients. The role of MET-PET during subsequent follow-up (FU) is unclear. We analyzed the uptake of ¹¹C-Methionine before and after stereotactic radiotherapy (SRT) in patients with a complex meningioma and investigated if there was a difference between patients with progressive disease (PD) and stable disease (SD) during FU.</p><h3>Methods</h3><p>This retrospective study investigates 62 MET-PETs in 29 complex meningioma patients. Standardized uptake value (SUV)_max and SUV_peak tumor-to-normal ratios (T/N-ratios) were calculated, comparing the tumor region with both the mirroring intracranial area and the right frontal gray matter. The difference in ¹¹C-Methionine uptake pre- and post-SRT was analyzed, as well as the change in uptake between PD or SD.</p><h3>Results</h3><p>Median (IQR) FU duration was 67 months (50.5–91.0). The uptake of ¹¹C-Methionine in meningiomas remained increased after SRT. Neither a statistically significant difference between MET-PETs before and after SRT was encountered, nor a significant difference in one of the four T/N-ratios between patients with SD versus PD with median (IQR) SUV_max T/N_{R front} 2.65 (2.13–3.68) vs 2.97 (1.55–3.54) [<i>p</i> = 0.66]; SUV_max T/N_mirror 2.92 (2.19–3.71) vs 2.95 (1.74–3.60) [<i>p</i> = 0.61]; SUV_peak T/N_{R front} 2.35 (1.64–3.40) vs 2.25 (1.44–3.74) [<i>p</i> = 0.80]; SUV_peak T/N_mirror 2.38 (1.91–3.36) vs 2.35 (1.56–3.72) [<i>p</i> = 0.95].</p><h3>Conclusions</h3><p>Our data do not support use of MET-PET during FU of complex intracranial meningiomas after SRT. MET-PET could not differentiate between progressive or stable disease.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 8","pages":"596 - 606"},"PeriodicalIF":2.5,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11282149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140890814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Animal PET scanner with a large field of view is suitable for high-throughput scanning of rodents","authors":"Yuki Tomonari,&nbsp;Yuya Onishi,&nbsp;Fumio Hashimoto,&nbsp;Kibo Ote,&nbsp;Takashi Okamoto,&nbsp;Hiroyuki Ohba","doi":"10.1007/s12149-024-01937-1","DOIUrl":"10.1007/s12149-024-01937-1","url":null,"abstract":"<div><h3>Objective</h3><p>In preclinical studies, high-throughput positron emission tomography (PET) imaging, known as simultaneous multiple animal scanning, can reduce the time spent on animal experiments, the cost of PET tracers, and the risk of synthesis of PET tracers. It is well known that the image quality acquired by high-throughput imaging depends on the PET system. Herein, we investigated the influence of large field of view (FOV) PET scanner on high-throughput imaging.</p><h3>Methods</h3><p>We investigated the influence of scanning four objects using a small animal PET scanner with a large FOV. We compared the image quality acquired by four objects scanned with the one acquired by one object scanned using phantoms and animals. We assessed the image quality with uniformity, recovery coefficient (RC), and spillover ratio (SOR), which are indicators of image noise, spatial resolution, and quantitative precision, respectively. For the phantom study, we used the NEMA NU 4-2008 image quality phantom and evaluated uniformity, RC, and SOR, and for the animal study, we used Wistar rats and evaluated the spillover in the heart and kidney.</p><h3>Results</h3><p>In the phantom study, four phantoms had little effect on imaging quality, especially SOR compared with that for one phantom. In the animal study as well, four rats had little effect on spillover from the heart muscle and kidney cortex compared with that for one rat.</p><h3>Conclusions</h3><p>This study demonstrated that an animal PET scanner with a large FOV was suitable for high-throughput imaging. Thus, the large FOV PET scanner can support drug discovery and bridging research through rapid pharmacological and pathological evaluation.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 7","pages":"544 - 552"},"PeriodicalIF":2.5,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140875658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of combining clinical factors, 18F-FDG PET-based intensity, volumetric features, and deep learning predictor in patients with EGFR-mutated lung adenocarcinoma undergoing targeted therapies: a cross-scanner and temporal validation study","authors":"Kun-Han Lue,&nbsp;Yu-Hung Chen,&nbsp;Sung-Chao Chu,&nbsp;Chih-Bin Lin,&nbsp;Tso-Fu Wang,&nbsp;Shu-Hsin Liu","doi":"10.1007/s12149-024-01936-2","DOIUrl":"10.1007/s12149-024-01936-2","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the prognostic value of ¹⁸F-FDG PET-based intensity, volumetric features, and deep learning (DL) across different generations of PET scanners in patients with epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma receiving tyrosine kinase inhibitor (TKI) treatment.</p><h3>Methods</h3><p>We retrospectively analyzed the pre-treatment ¹⁸F-FDG PET of 217 patients with advanced-stage lung adenocarcinoma and actionable EGFR mutations who received TKI as first-line treatment. Patients were separated into analog (<i>n</i> = 166) and digital (<i>n</i> = 51) PET cohorts. ¹⁸F-FDG PET-derived intensity, volumetric features, ResNet-50 DL of the primary tumor, and clinical variables were used to predict progression-free survival (PFS). Independent prognosticators were used to develop prediction model. Model was developed and validated in the analog and digital PET cohorts, respectively.</p><h3>Results</h3><p>In the analog PET cohort, female sex, stage IVB status, exon 19 deletion, SUV_max, metabolic tumor volume, and positive DL prediction independently predicted PFS. The model devised from these six prognosticators significantly predicted PFS in the analog (HR = 1.319, <i>p</i> &lt; 0.001) and digital PET cohorts (HR = 1.284, <i>p</i> = 0.001). Our model provided incremental prognostic value to staging status (c-indices = 0.738 vs. 0.558 and 0.662 vs. 0.598 in the analog and digital PET cohorts, respectively). Our model also demonstrated a significant prognostic value for overall survival (HR = 1.198, <i>p</i> &lt; 0.001, c-index = 0.708 and HR = 1.256, <i>p</i> = 0.021, c-index = 0.664 in the analog and digital PET cohorts, respectively).</p><h3>Conclusions</h3><p>Combining ¹⁸F-FDG PET-based intensity, volumetric features, and DL with clinical variables may improve the survival stratification in patients with advanced EGFR-mutated lung adenocarcinoma receiving TKI treatment. Implementing the prediction model across different generations of PET scanners may be feasible and facilitate tailored therapeutic strategies for these patients.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 8","pages":"647 - 658"},"PeriodicalIF":2.5,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140858690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of 68 Ga-FAPI PET/CT in patients with bone metastases in various cancers","authors":"Hacı Arak,&nbsp;Umut Elboga,&nbsp;Yusuf Burak Cayirli,&nbsp;Aydın Aytekin","doi":"10.1007/s12149-024-01935-3","DOIUrl":"10.1007/s12149-024-01935-3","url":null,"abstract":"<div><h3>Objective</h3><p>This study aimed to compare ¹⁸FDGPET/CT in patients who develop bone metastases due to various cancers and to investigate the prognostic significance of the ⁶⁸FAPI-PET/CT SUVmax value for survival.</p><h3>Methods</h3><p>Patients with bone metastases who underwent both ⁶⁸ Ga-FAPI PET/CT and ¹⁸FDGPET/CT within a 1 week period were included in this retrospective study. The effect of the SUVmax value of bone lesions on overall survival was analyzed.</p><h3>Results</h3><p>A total of 75 eligible patients with 139 bone lesions were included in this study. The median age of the patients was 55 (30–83) and 48(64%) patients were newly diagnosed. The primary lesion median ⁶⁸ Ga-FAPI PET/CT SUVmax value was higher than the median ¹⁸FDGPET/CT SUVmax (10.75 versus 6.7). Bone lesions ⁶⁸ Ga-FAPI PET/CT SUVmax median (IQR) were 7.8 (4.6–13.2), and ¹⁸FDGPET/CT SUVmax of bone lesions were 5.9 (3.8–8.2). More bone lesions were detected on ⁶⁸ Ga-FAPI PET/CT than on ¹⁸FDGPET/CT(median IQR 4 [1–9] versus 2 [1–6] (<i>p</i> = 0.014). The extra lesions observed on ⁶⁸ Ga-FAPI PET/CT were mostly sclerotic bone lesions (<i>p</i> = 0.001).⁶⁸ Ga-FAPI PET/CT SUVmax was significantly higher in vertebra and thorax lesions (<i>p</i> = 0.011 and <i>p</i> = 0.018, respectively). While the bone lesion ⁶⁸ Ga-FAPI PET/CT SUVmax affected the OS, the ¹⁸FDGPET/CT SUVmax value did not affect the OS (<i>p</i> &lt; 0.001 and <i>p</i> = 0.079, respectively). In ROC analysis, a cut-off-off value of ⁶⁸ Ga-FAPI PET/CT SUVmax &gt; 7.7 was found for OS (AUC: 0.619). The median OS in the group above the cut-off value was worse than that in the group below the cut-off value (32 versus 45) months (<i>p</i> = 0.002). In the multivariate analysis for OS, the ⁶⁸ Ga-FAPI PET/CT SUVmax of bone lesions was an important parameter, as well as cancer subtype, ALP level, and disease occurrence.</p><h3>Conclusions</h3><p>⁶⁸ Ga-FAPI PET/CT detected more bone lesions and higher SUVmax values than ¹⁸FDGPET/CT in various cancers. The prognostic value of the SUVmax value of ⁶⁸ Ga-FAPI PET/CT bone lesions was observed regardless of disease subtype.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 8","pages":"630 - 638"},"PeriodicalIF":2.5,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140837504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fundamental evaluation regarding the relationship between albumin-binding and tumor accumulation of PSMA-targeting radioligands","authors":"Nobuki Kazuta,&nbsp;Shohei Tsuchihashi,&nbsp;Hiroyuki Watanabe,&nbsp;Masahiro Ono","doi":"10.1007/s12149-024-01930-8","DOIUrl":"10.1007/s12149-024-01930-8","url":null,"abstract":"<div><h3>Objective</h3><p>The marked success of prostate-specific membrane antigen (PSMA)-targeting radioligands with albumin binder (ALB) is attributed to the improvement of blood retention and tumor accumulation. [¹¹¹In]In-PNT-DA1, our PSMA-targeting radioligand with ALB, also achieved improved tumor accumulation due to its prolonged blood retention. Although the advantage of ALBs is related to their reversible binding to albumin, the relationship between albumin-binding and tumor accumulation of PSMA-targeting radioligands remains unclear because of the lack of information about radioligands with stronger albumin-binding than ALBs. In this study, we designed and synthesized [¹¹¹In]In-PNT-DM-HSA, a new radioligand that consists of a PSMA-targeting radioligand covalently bound to albumin. The pharmacokinetics of [¹¹¹In]In-PNT-DM-HSA was compared with those of [¹¹¹In]In-PNT-DA1 and [¹¹¹In]In-PSMA-617, a non-ALB-conjugated radioligand, to evaluate the relationship between albumin-binding and tumor accumulation.</p><h3>Method</h3><p>The [¹¹¹In]In-PNT-DM-HSA was prepared by incubation of [¹¹¹In]In-PNT-DM, a PSMA-targeting radioligand including a maleimide group, and human serum albumin (HSA). The ability of [¹¹¹In]In-PNT-DM-HSA was evaluated by in vitro assays. A biodistribution study using LNCaP tumor-bearing mice was conducted to compare the pharmacokinetics of [¹¹¹In]In-PNT-DM-HSA, [¹¹¹In]In-PNT-DA1, and [¹¹¹In]In-PSMA-617.</p><h3>Results</h3><p>The [¹¹¹In]In-PNT-DM-HSA was obtained at a favorable radiochemical yield and high radiochemical purity. In vitro assays revealed that [¹¹¹In]In-PNT-DM-HSA had fundamental characteristics as a PSMA-targeting radioligand interacting with albumin covalently. In a biodistribution study, [¹¹¹In]In-PNT-DM-HSA and [¹¹¹In]In-PNT-DA1 showed higher blood retention than [¹¹¹In]In-PSMA-617. On the other hand, the tumor accumulation of [¹¹¹In]In-PNT-DA1 was much higher than [¹¹¹In]In-PNT-DM-HSA and [¹¹¹In]In-PSMA-617.</p><h3>Conclusions</h3><p>These results indicate that the moderate reversible binding of ALB with albumin, not covalent binding, may play a critical role in enhancing the tumor accumulation of PSMA-targeting radioligands.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 7","pages":"574 - 583"},"PeriodicalIF":2.5,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140798043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of regional and total skeletal metabolism using 18F-NaF PET/CT in patients with chronic kidney disease","authors":"Sharjeel Usmani,&nbsp;Najeeb Ahmed,&nbsp;Gopinath Gnanasegaran,&nbsp;Fahad Marafi,&nbsp;Ahmed Bani-Mustafa,&nbsp;Tim Van den Wyngaert","doi":"10.1007/s12149-024-01929-1","DOIUrl":"10.1007/s12149-024-01929-1","url":null,"abstract":"<div><h3>Objective</h3><p>The study aims to assess regional and total bone metabolic activity in patients with chronic kidney disease using Na[¹⁸F]F PET and correlation between semi-quantitative indices and blood parameters.</p><h3>Methods</h3><p>Seventy-two subjects (mean age 61.8 ± 13.8 years) were included. Of these 24/72 patients had end-stage renal disease (ESRD) (GFR &lt; 15 mL/min/1.73 m²), 38/72 had chronic kidney disease (CKD) (GFR between 60 and 15 mL/min/1.73 m²), and 10/72 were controls with normal renal function. All subjects underwent Na[¹⁸F]F PET-CT with a dose activity of 0.06 mCi/Kg. Regional and total skeletal metabolism were assessed with mean SUVs in a skeletal volume of interest (VOI), bone to soft tissue index (B/S), global SUV mean (GSUV mean) of the whole bone, and uptake in the femoral neck.</p><h3>Results</h3><p>Statistically significant differences were observed in a number of ¹⁸F-NaF metrics like femoral neck metabolism in CKD and ERSD groups in comparison to control in right (<i>P</i> = 0.003) and left femur (<i>P</i> = 0.006), bone to soft tissue index in the femur (<i>P</i> = 0.016) and GSUV₅ (<i>P</i> = 0.006). There is also a significant difference in SUV mean in lumbar vertebrae (L1–L4) among CKD, ESRD, and controls. There was a moderate correlation between ¹⁸F-NaF PET scan uptake and blood parameters such as ALP and PTH. Na[¹⁸F]F uptake parameters were significantly different in low versus high bone turnover state.</p><h3>Conclusions</h3><p>The assessment of total skeleton and regional metabolism and bone turnover in CKD patients is feasible with Na[¹⁸F]F PET. Na[¹⁸F]F can help to detect early changes in bone metabolism and assess the progression of bone disease in this complex condition. Quantification with Na[¹⁸F]F PET might provide better assessment of the bone turnover. The difference in Na[¹⁸F]F uptake in CKD compared to controls is likely related to a change in bone turnover which, however, requires further validation.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 7","pages":"563 - 573"},"PeriodicalIF":2.5,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140797968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis","authors":"Naoto Wakabayashi,&nbsp;Shiro Watanabe,&nbsp;Takashige Abe,&nbsp;Junki Takenaka,&nbsp;Kenji Hirata,&nbsp;Rina Kimura,&nbsp;Keita Sakamoto,&nbsp;Nobuo Shinohara,&nbsp;Kohsuke Kudo","doi":"10.1007/s12149-024-01928-2","DOIUrl":"10.1007/s12149-024-01928-2","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the incidence of adverse events (AEs) following single and multiple administrations of I-131 metaiodobenzylguanidine (MIBG) therapy for inoperable pheochromocytomas and paragangliomas (PPGLs).</p><h3>Methods</h3><p>A single-center retrospective study was conducted on patients with inoperable PPGLs who underwent I-131 MIBG therapy between January 2000 and December 2020. A total of 28 patients with available electronic medical records were included. The treatment consisted of a single intravenous administration of 150 mCi (5.55 GBq) of I-131 MIBG. We evaluated the first MIBG treatment and repeated MIBG treatments performed within 200 days of the previous treatment. AEs for each treatment were evaluated using CTCAE version 4.0, and the statistical analysis was conducted at a significance level of <i>p</i> &lt; 0.05. Objective response based on RECIST 1.1 criteria and biochemical response based on urinary catecholamines were assessed.</p><h3>Results</h3><p>The study included a total of 63 administrations, consisting of 28 single administrations (SAs), including the first administration for all 28 cases, and 35 multiple administrations (MAs), which included the second or later administrations. Hematological AEs were evaluable for 23 SAs and 29 MAs. Grade 3 or higher leukopenia occurred in 9.8% of all administrations, and Grade 3 or higher lymphopenia in 23.5%; both were manageable through observation. There were no significant differences in clinical AE Grades 1–2 (<i>p</i> = 0.32), hematological AE Grades 1–2 (<i>p</i> = 0.22), or hematological AE Grades 3–4 (<i>p</i> = 0.12) between MAs and SAs. Statistical analysis for each type of AE revealed significant increases in leukopenia (<i>p</i> &lt; 0.01) and lymphopenia (<i>p</i> = 0.04). No significant difference in anemia, thrombocytopenia, or neutropenia was observed between MAs and SAs. There was no significant increase in the incidence rate of Grade 3 or higher hematological AEs for any of the parameters. The objective response rate was 0% for SAs and 36% for MAs. Biochemical response rates were 18% for SAs and 67% for MAs.</p><h3>Conclusion</h3><p>In I-131 MIBG therapy for PPGLs, multiple administrations significantly increased only Grade 1 or 2 lymphopenia and leukopenia compared to single administration.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 7","pages":"553 - 562"},"PeriodicalIF":2.5,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140664251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}